KYMERA THERAPEUTICS, INC. Restricted Cash and Cash Equivalents
KYMERA THERAPEUTICS, INC. (KYMR) had Restricted Cash and Cash Equivalents of $1.79 million as of 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Balance Sheet
us-gaap:RestrictedCashAndCashEquivalents · last filed 2020-11-05
- 2020-09-30: Restricted Cash and Cash Equivalents $1.79M.
- 2019-09-30: Restricted Cash and Cash Equivalents $199.00K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2020-09-30 | $1.79M 10-Q · filed 2020-11-05 |
| 2019-09-30 | $199.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |